Abstract：The patient, a male newborn, was admitted to the hospital 2 hours after birth due to prematurity (gestational age 27+5 weeks) and respiratory distress occurring 2 hours postnatally. After admission, the infant developed fever and elevated C-reactive protein levels. On the fourth day after birth, metagenomic next-generation sequencing of cerebrospinal fluid indicated a positive result for Mycoplasma hominis (9 898 reads). On the eighth day, a retest of cerebrospinal fluid metagenomics confirmed Mycoplasma hominis (56 806 reads). The diagnosis of purulent meningitis caused by Mycoplasma hominis was established, and the antibiotic treatment was switched to moxifloxacin [5 mg/(kg·day)] administered intravenously for a total of 4 weeks. After treatment, the patient's cerebrospinal fluid tests returned to normal, and he was discharged as cured on the 76th day after birth. This article focuses on the diagnosis and treatment of neonatal Mycoplasma hominis purulent meningitis, introducing the multidisciplinary diagnosis and treatment of the condition in extremely preterm infants.
MAO Wei-Ying,LAN Jiang-Er,GAN Ming-Yu et al. Moxifloxacin treatment for Mycoplasma hominis meningitis in an extremely preterm infant[J]. CJCP, 2024, 26(4): 432-436.
Waites KB, Duffy LB, Crouse DT, et al. Mycoplasmal infections of cerebrospinal fluid in newborn infants from a community hospital population[J]. Pediatr Infect Dis J, 1990, 9(4): 241-245. PMID: 2336309. DOI: 10.1097/00006454-199004000-00004.
Waites KB, Rudd PT, Crouse DT, et al. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of central nervous system in preterm infants[J]. Lancet, 1988, 1(8575/6): 17-21. PMID: 2891889. DOI: 10.1016/s0140-6736(88)91002-1.
Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years[J]. Clin Microbiol Infect, 2010, 16(11): 1649-1655. PMID: 20047607. DOI: 10.1111/j.1469-0691.2009.03155.x.
Ahmadi MH. Resistance to tetracyclines among clinical isolates of Mycoplasma hominis and Ureaplasma species: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2021, 76(4): 865-875. PMID: 33367765. DOI: 10.1093/jac/dkaa538.
Wildenbeest JG, Said I, Jaeger B, et al. Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin[J]. Lancet Infect Dis, 2016, 16(11): e261-e266. PMID: 27641775. DOI: 10.1016/S1473-3099(16)30162-1.
Nohren J, Namtu K, Peloquin C, et al. The pharmacokinetics of moxifloxacin in cerebrospinal fluid following intravenous administration: a report of successfully treated infant with Mycoplasma hominis meningitis[J]. Pediatr Infect Dis J, 2020, 39(8): e183-e184. PMID: 32195773. DOI: 10.1097/INF.0000000000002655.
Yeung T, Chung E, Chen J, et al. Therapeutic drug monitoring of moxifloxacin to guide treatment of Mycoplasma hominis meningitis in an extremely preterm infant[J]. J Pediatr Pharmacol Ther, 2021, 26(8): 857-862. PMID: 34790077. PMCID: PMC8592008. DOI: 10.5863/1551-6776-26.8.857.
Kersin SG, Bozan T, ?zdemir H, et al. Clinical and laboratory awareness for an under recognized pathogen in newborn meningitis: Mycoplasma hominis: a case report[J]. Turk J Pediatr, 2020, 62(2): 280-283. PMID: 32419421. DOI: 10.24953/turkjped.2020.02.015.
